News SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Real-time Estimate Cboe BZX Other stock markets 09:32:49 02/05/2024 pm IST			5-day change	1st Jan Change
43.04 ^USD	-8.11%		-1.30%	+19.52%

05:24pm	SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss	MT
12:39pm	Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss	08:54pm	MT
SpringWorks Therapeutics: Q1 Earnings Snapshot	04:15pm	AQ
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M	04:09pm	MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04:02pm	CI
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates	04:00pm	GL
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04	GL
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024	18/04	GL
Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM	12/03
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating	06/03	MT
HC Wainwright Raises Price Target on SpringWorks Therapeutics to $74 From $73, Maintains Buy Rating	06/03	MT
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment	04/03	MT
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	04/03	GL
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	04/03	CI
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	29/02	GL
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	29/02	AQ
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows	27/02	MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02	CI
SpringWorks Therapeutics: Q4 Earnings Snapshot	27/02	AQ
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q4 Revenue $5.4M	27/02	MT
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates	27/02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Summary

Filters